{"GHMDC classification":["Preventative"],"GHMDC health topic":["Maternal mortality"],"GHMDC manufacturer coordinates":["-37.915802777778, 145.13138611111"],"GHMDC manufacturer location":["Clayton, Australia"],"GHMDC scope":["Clinical trial"],"Page SDG":["SDG03 Good health and well-being"],"Page URL":["https://www.appropedia.org/Global_Health_Medical_Device_Compendium/Aerosol_Oxytocin_Delivery_System"],"Page affiliations":["Appropedia Foundation","University of Michigan"],"Page authors":["User:Lonny","User:Chriswaterguy","User:Emilio","Kathleen Sienko","Amir Sabet Sarvestani"],"Page description":["Postpartum hemorrhage is the leading cause of maternal mortality across the world. Although there is a safe and effective drug, oxytocin, that is widely administered to prevent excessive bleeding, the method of administration is often risky in resource-poor settings. Currently, oxytocin can only be administered via injection into the bloodstream by trained medical personnel, and furthermore, the drug needs to be refrigerated to retain its effects. Thus, administration of oxytocin requires sterile equipment, clean water, skilled practitioners, and electricity, all of which are not easily feasible in many developing countries."],"Page image":["File:Lung.jpg"],"Page language":["en"],"Page license":["CC-BY-SA-3.0"],"Page parent":["Global Health Medical Device Compendium"],"Page root":["Global Health Medical Device Compendium"],"Page title":["Global Health Medical Device Compendium/Aerosol Oxytocin Delivery System"],"Page views":[195],"Page year":["Sunday, 01-Jan-12 00:00:00 UTC"],"Modification date":["Thursday, 10-Sep-26 13:57:18 UTC"]}